Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

Published:2015-01-21 Issue:8 Volume:56 Page:2439-2447
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tonino Sanne H.,Mulkens Chantal E.,van Laar Jacoline,Derks Ingrid A. M.,Suo Guangli,Croon-de Boer Fransien,van Oers Marinus H. J.,Eldering Eric,Wang Jean Y.,Kater Arnon P.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.996751

Reference49 articles.

1. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response

2. Survival of Young Patients with Chronic Lymphocytic Leukemia Failing Fludarabine Therapy: A Basis for the Use of Myeloablative Therapies

3. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

4. How will B-cell-receptor–targeted therapies change future CLL therapy?

5. Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxidative Stress Player in Head and Neck Cancer Therapy Response;Interdisciplinary Cancer Research;2022

2. The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development;Acta Naturae;2021-11-15

3. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells;Anti-Cancer Drugs;2021-09-13

4. Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine;Leukemia & Lymphoma;2019-02-04

5. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study;Bone Marrow Transplantation;2016-02-15